On the open plains of modern oncology, the checkpoint inhibitor stalks its prey with elegance - until, without warning, it also tackles the furniture, the curtains, and occasionally your heart. Nature is beautiful. Nature is also a terrible project manager.
That is the basic mess behind a new rapid response in Journal for ImmunoTherapy of Cancer, where Lingrong Tang and colleagues weigh in on an underdog idea: using JAK inhibitors to calm severe immune-related side effects from checkpoint immunotherapy without fully unplugging the anticancer immune response [1].
The problem: your bodyguards got a little too enthusiastic
Checkpoint inhibitors work by taking the brakes off immune cells, especially T cells, so they can attack cancer. Great for tumors. Less great when those same revved-up cells decide the colon, lungs, liver, joints, or heart also look suspicious. Those toxicities are called immune-related adverse events, or irAEs, and they can be mild, miserable, or flat-out dangerous [2,3].
Standard treatment usually starts with corticosteroids. Steroids are the medical equivalent of throwing a heavy blanket over the whole immune system and hoping the small kitchen fire does not spread to the rest of the house. That often works. But not always. Some irAEs laugh in the face of steroids and keep marching, especially severe myocarditis, colitis, pneumonitis, or inflammatory arthritis [4]. That is where clinicians start looking for more targeted tools.
Enter JAK inhibitors, the weird little long shot
JAK inhibitors block the JAK-STAT pathway, one of the immune system's main signal relays for inflammatory cytokines. If cytokines are the screaming group chat of inflammation, JAK proteins help deliver the messages. Shut that pathway down, and you can lower the volume.
Here is the catch. That same pathway also helps support antitumor immune activity in some settings. So oncologists have had a fair concern: if you use a JAK inhibitor to stop an irAE, are you also sending the anti-cancer T cells out for an early lunch break?
Tang and colleagues argue the answer is not a simple yes or no. It depends on context - timing, dose, tissue, and which immune cells are running the chaos [1]. Cancer biology, once again, refuses to behave like a tidy spreadsheet.
Why this paper caught attention
The rapid response comments on a prospective cohort study by Habib and colleagues that treated steroid-refractory or life-threatening irAEs with JAK inhibitors, mostly tofacitinib. Clinical remission was reported in about 71% of evaluable patients, with a median time to resolution of 41 days. The signal looked especially notable in myocarditis and inflammatory arthritis, and the short-term safety profile was encouraging [1,5].
That is not proof of a new standard of care. It is a small, early clinical signal. But in the land of severe irAEs, where options can get ugly fast, a 70-ish percent remission rate gets your attention in the same way a backup goalie scoring a playoff goal gets your attention.
Plot twist: blocking JAK does not always ruin immunotherapy
This is the part that makes the story more interesting than "drug calms inflammation, film at 11."
Recent studies suggest JAK inhibition can sometimes reshape the immune environment in useful ways rather than simply smothering it. In metastatic non-small cell lung cancer, sequential JAK1 inhibition paired with PD-1 blockade was associated with improved immune function and a 67% response rate in a phase 2 study [6]. In Hodgkin lymphoma, ruxolitinib plus nivolumab produced responses in patients whose disease had already resisted checkpoint therapy [7].
That does not mean JAK inhibitors are secret immunotherapy sidekicks for everyone. It means the immune system is less like a light switch and more like an ancient hotel boiler with handwritten labels and one cursed valve nobody fully trusts. Sometimes turning one dial down actually helps the whole machine run better.
What this could mean in the real world
If these results hold up, JAK inhibitors could become a more precise rescue option for people with severe irAEs, especially when broad immunosuppression is not enough or may carry its own costs. That matters because checkpoint toxicities are one of the biggest reasons life-saving immunotherapy gets interrupted or stopped [2-4].
It also points to a bigger shift in the field. Instead of treating every dangerous irAE with the same immune sledgehammer, oncology is inching toward targeted immunomodulation - matching the rescue drug to the biology of the toxicity. Which, frankly, is how medicine should behave when it has had enough coffee.
Still, there are real limits here. The evidence is early. The cohorts are small. Follow-up is short. JAK inhibitors have their own baggage, including infection and other safety concerns in broader use. No one should read this and think, "Excellent, we have solved immunotherapy toxicity." We have not. We have maybe found a scrappy bench player who deserves more minutes.
References
-
Tang L, Mo W, Li N, Tian G. Rapid response: Context-dependent immunomodulatory effects of JAK inhibition in the management of severe immune-related adverse events. J Immunother Cancer. 2026. doi:10.1136/jitc-2025-014677. PubMed: 42031428
-
Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nature Cancer. 2024;5:557-571. doi:10.1038/s43018-024-00730-3
-
Verheijden RJ, van Eijs MJJ, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. Immuno-Oncology Technology. 2023;7(1):41. PubMed: 37173424
-
Daetwyler E, Wallrabenstein T, König D, Cappelli LC, Naidoo J, Zippelius A, Läubli H. Corticosteroid-resistant immune-related adverse events: a systematic review. J Immunother Cancer. 2024;12(1):e007409. doi:10.1136/jitc-2023-007409. PMCID: PMC10806650
-
Habib R, Miller WH, Papadopoulos T, Del Rincon SV, Berger C, Flores Molina M, Hudson M, Esfahani K. JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study. J Immunother Cancer. 2025;13:e013214. doi:10.1136/jitc-2025-013214. PMCID: PMC12666022
-
Mathew D, Marmarelis ME, Foley C, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384(6702):eadf1329. doi:10.1126/science.adf1329. PubMed: 38900877
-
Zak J, Pratumchai I, Marro BS, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384(6702):eade8520. doi:10.1126/science.ade8520. PubMed: 38900864
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.